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Abstract: Constipation is a common symptom in palliative care patients which can generate 
considerable suffering. There is uncertainty about the choice of treatment options from varying 
recommendations for management of constipation and a varying clinical practice in palliative 
care settings. The purpose of the review was to evaluate the current recommendations of therapy 
guidelines for the management of opioid-induced constipation in palliative care patients with 
a focus on methylnaltrexone bromide. Recent findings in the literature and related information 
on the opioid-induced gastrointestinal disorders in patients with advanced illness, as well as 
information on the opioid-antagonist methylnaltrexone, are discussed. Knowledge of the role of 
definitions, the causes of constipation and the pathophysiology of opioid-induced constipation 
must be given high priority in the treatment of patients receiving opioids. Diagnosis and therapy 
of constipation, therefore, should relate to findings in clinical investigation. Opioid-induced 
constipation and its adequate treatment is an important issue for patients with advanced illness 
and also poses therapeutic challenge for clinicians in daily routine. Methylnaltrexone bromide 
may represent an important therapeutic option for palliative care patients who are suffering from 
opioid-induced constipation with failure of conventional prophylactic oral laxative treatment.
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Introduction
Constipation is a distressing complication for oncology patients that is often 
underassessed and undertreated and may occur as a side effect of tumor growth or an 
adverse effect of drug therapy. However, constipation is one of the most frequent and 
persistent side effects of opioid therapy, and it is feared by many patients as much 
as the symptom of pain. Prophylaxis and symptomatic treatment of opioid-induced 
constipation are essential and the most effective approach to its management. Unlike 
other side effects of opioid medication, such as nausea and emesis, there is no, or 
extremely slow, tolerance build-up to the constipatory effects of opioids. In patients 
with incurable progressive and far-advanced disease, for whom prognosis is limited 
and the focus of care is on the quality of life, opioid-induced constipation remains a 
significant clinical problem. Particularly in patients with advanced-stage tumor disease 
treatment must be undertaken with careful consideration of their physical activity and 
dietary needs.
The prevalence of constipation in patients with cancer ranges from 70% to 100%.1–3 
In general terms, all patients treated with opioids will require some degree of clinical 
intervention to relieve the discomfort imposed by constipation. The evidence suggests 
that up to 90% of patients treated with opioids will experience chronic constipation Therapeutics and Clinical Risk Management 2010:6 78
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and of those receiving standard laxative treatments over half 
will remain dissatisfied with the outcome.1 Furthermore, the 
treatment of constipation, in general, carries an economic 
burden for the health system, in terms of the costs associated 
with hospital admissions and length of stay.
Although few evidence-based data exist on the specific 
use of laxatives in palliative medicine,4,5 long years of clinical 
experience have yielded therapeutic recommendations.4,6,7
Constipation
The term constipation describes the subjective impression 
that the contents of the intestine are not evacuated at adequate 
frequency, in adequate volumes, the consistency of the stool 
is too hard, or/and the stool is passed with discomfort.8,9
Untreated constipation can contribute to secondary com-
plications such as abdominal distension, urinary retention, 
nausea, vomiting, and anorexia, as well as the development of 
hemorrhoids, anal fissures, perianal abscesses, and intestinal 
obstruction.1,7,10–13 Constipation may be annoying and uncom-
fortable and can lead to life-threatening fecal impaction. 
Patients with fecal impaction may present with circulatory, 
cardiac, or respiratory symptoms instead of gastrointestinal 
symptoms.1,7,10–13
In advanced-stage tumor disease, constipation is a fre-
quent symptom. In the palliative care setting it occurs par-
ticularly in immobile patients, whose diet is not rich enough 
in fiber and who drink too little fluid. In addition, they often 
take drugs that induce constipation, such as opioids. Since 
these patients can increase neither their physical activity nor 
their fluid and food/fiber intake, treatment with laxatives is 
indicated at an early stage and always at the start of opioid 
therapy. It is known that constipation occurs more often 
in women and that the incidence of constipation increases 
with age.14–16
Differentiating between the normal range of evacuation 
of stools and a diagnosis of constipation is not always easy. 
Table 1 provides indicators for differentiation.16–18 Consti-
pation can be drug-induced or have organic or functional 
causes (Table 2).16–18
Pathophysiology of opioid-induced 
constipation
Opioid-induced constipation is predominantly mediated by 
gastrointestinal µ-opioid receptors.19,20
Peripheral as well as intrathecal and intraventricular 
administration of opioids will lead to a prolonged colon 
passage of the bowel content, since opioid-induced consti-
pation is caused by linkage of the opioid receptors in the 
gut and the central nervous system.21,22 The inhibition of the 
release of acetylcholine from the myenteric plexus leads to 
a relaxation of the longitudinal musculature of the colon and 
small intestine. Subsequently, the propulsive motor activity 
decreases. Furthermore, opioids cause an increase in seg-
mental intestinal contraction. This will cause a prolonged 
transit of intestinal contents, leading to a withdrawal of water 
and fecal impaction. Further, the intestinal, gastric, biliary, 
and pancreatic secretions decrease. An increase in the tonus 
of the intestinal sphincters and a decrease in the defecatory 
reflex add to the constipatory effect. Meissner et al in an 
unrandomized controlled study, showed that enteral appli-
cation of naloxone can reduce opioid-induced constipation 
without impairing or suspending the pain-relieving effects 
of the opioid.23 A combination drug consisting of the opioid 
oxycodone and the opioid antagonist naloxone has been 
available for some time. Shaiova et al reviewed the role of 
methylnaltrexone, a peripheral opioid receptor antagonist, in 
the management of opioid-induced constipation.24
Treating opioid-induced constipation 
in palliative care patients
In palliative medicine, the functional causes of constipation 
far exceed the organic ones, and opioid-induced constipa-
tion is of particular importance. If drugs are the cause of 
constipation then consideration needs to be given to stopping 
these drugs. This is, however, not sensible in the context of 
analgesia with opioids.
The pharmacological management of opioid-induced 
constipation generally involves two approaches: nonspecific 
Table 1 Differentiation between normal stool evacuation and constipation
Variable Normal Constipation likely
Frequency of stools 3 evacuations per week 
and 3 evacuations per day
3 evacuations per week
weight of stools 35–150 g/day 35 g/day
weight of water in stools ca 70% 70%
Time taken by gastrointestinal passage 2–5 days 5 daysTherapeutics and Clinical Risk Management 2010:6 79
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treatment with laxatives and prokinetic drugs, and specific 
treatment with opioid receptor antagonists.10,23,25
Prophylactic treatment with laxatives should be initi-
ated and sustained, for as long as the opioid is given. The 
choice of substance(s) for symptomatic drug treatment with 
laxatives has to be made accordingly. Often synergism of 
multiple categories of agents is required for successful 
laxation.
Laxatives (Latin: laxare – to loosen) are substances that 
accelerate defecation. Most laxatives improve the consistency 
of the stools by luminal water retention or by increasing 
the secretion of water into the lumen of the intestine and/or 
stimulating peristalsis.16
If the nonspecific regimens do not provide satisfactory 
relief from the gastrointestinal manifestations of opioid-
induced constipation, specific treatment options with 
peripherally restricted opioid receptor antagonists such as 
methylnaltrexone bromide may be more efficacious for 
treatment of opioid-induced constipation and may thereby 
improve bowel function.
Methylnaltrexone bromide
One of the substances investigated for the treatment of 
opioid-induced constipation is methylnaltrexone, a quater-
nary derivate of the pure opioid-antagonist naltrexone, which 
results in a distinct pharmacological profile.11,26 Methylnal-
trexone was developed at the University of Chicago, USA, 
and out-licensed to UR Labs in 1985. N-methylation of the 
uncharged systemic opioid antagonist, naltrexone,27 results 
in a charged derivative, methylnaltrexone, which has proven 
ability to cross the blood–brain barrier in humans because of 
its polarity and low lipid solubility.11,28
A number of phase I and II studies have established the 
pharmacodynamic, pharmacokinetic, therapeutic and safety 
profile of methylnaltrexone.29–32
The drug has been formulated as a solution for intrave-
nous or subcutaneous administration and as capsules/tablets 
for oral administration. Both the parenteral and oral formula-
tions, as well as single and repeated dosage regimens have 
been found efficacious in preventing the opioid-induced 
prolongation of gastric emptying and orocecal transit time 
without significantly attenuating the analgesic effect of 
opioids.30,31,33 In this context it is no less interesting that 
methylnaltrexone may ameliorate opioid-induced urinary 
retention.33,34
Selective blockade of peripheral gastrointestinal µ-opioid 
receptors might relieve constipation without compromising 
centrally mediated effects of opioid analgesia or precipitat-
ing withdrawal.
In healthy volunteers, methylnaltrexone reversed the 
morphine-induced delay in both gastric emptying and 
oral–cecal transit time without affecting analgesia.33,35–39 
The efficacy and safety of methylnaltrexone bromide was 
demonstrated in two randomized, double-blind and placebo-
controlled studies, as well as in one single-blinded phase II 
study that also showed that methylnaltrexone rapidly induced 
laxation (Table 3).39–41 The patient groups in the studies by 
Yuan et al40,41 received methylnaltrexone for methadone-
induced constipation, and Thomas et al39 demonstrated their 
findings in patients with advanced illness and opioid-induced 
constipation.
In both studies, patients had advanced terminal illness and 
limited life expectancy, the majority having a primary diag-
nosis of incurable cancer; other primary diagnoses included 
end-stage chronic obstructive pulmonary disease, cardiovas-
cular disease/heart failure or other advanced illnesses. Prior to 
screening, patients had opioid-induced constipation defined 
as either 3 bowel movements in the preceding week or no 
bowel movement for 2 days.
Methylnaltrexone bromide-treated patients had a higher 
rate of laxation within 4 hours of the initial dose (48%) than 
placebo-treated patients (16%) (95% confidence interval 
[CI] 7% to 49%; P  0.0001). Methylnaltrexone bromide-
treated patients also had significantly higher rates of laxation 
within 4 hours after at least 2 of the first 4 doses (52%) 
than did placebo-treated patients (9%) (P  0.0001). Stool 
consistency was not meaningfully improved in patients who 
had soft stool at baseline. No episodes of generalized opioid 
withdrawal or a form of gut hypermotility known as “gut 
withdrawal syndrome” were observed, and there was no 
Table 2 Possible causes of constipation
Organic Functional  Drug-induced
Diverticulitis Prolonged colon  Opioids
Tumors passage Antibiotics
Inflammation in the  impaired defecation Anticholinergics
anal area Insufficient intake of  Antihypertensive drugs
Neurological  fluids Anticonvulsive drugs
disorders Low fiber diet Antidepressants
endocrine  immobility Drugs for Parkinson’s 
disorders disease
Metabolic causes Diuretics
Neuroleptics
Recto-anal disorders Antacids
MegacolonTherapeutics and Clinical Risk Management 2010:6 80
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evidence of antagonism of analgesia. Futhermore, in both 
studies there was no evidence to suggest differential effects 
of age or gender on safety or efficacy. The effect on race 
could not be analyzed because the study population was 
predominally Caucasian (88%).39,40
Although methylnaltrexone was significantly more effec-
tive than placebo, it was somewhat disappointing that in both 
phases of the study the drug produced rescue-free laxation in 
only about half of the patients. There may be several reasons 
for this relative high failure rate. For example, although all 
patients received opioids, the predominant causes of consti-
pation among the patients who did not respond to methylnal-
trexone could have been the effects of other drugs or disease 
processes unrelated to actions mediated by opioid receptors.42 
Additional explanations could be that methylnaltrexone may 
behave as a partial agonist.43
McNicol et al44 showed in a systematic review of four 
studies that, on average, gastrointestinal transit time in 
patients given methylnaltrexone was reduced by 52 minutes 
(95% CI –73 to –32 minutes) compared with placebo.36–38,40 
Methylnaltrexone reduced the mean transit time to 93 to 110 
from 140 to 163 minutes for placebo.
At therapeutic intravenous doses of 0.3 to 0.45 mg/kg and 
oral doses up to 19 mg/kg methylnaltrexone is well tolerated 
and able to relieve constipation in methadone-dependent 
individuals and patients with advanced illness who need 
opioids for pain control.30,45
The European Medicines Agency approved subcuta-
neous administration of methylnaltrexone for treatment 
of opioid-induced constipation in adults with advanced 
illness. Methylnaltrexone should be used in patients with 
opioid-induced bowel dysfunction who do not respond to a 
reasonable laxative regimen, in combination with the laxa-
tive regimen. The recommended dose is 8 mg for patients 
weighing 38 to 61 kg and 12 mg for patients weighing 62 to 
114 kg, every 2 days. Outside these weight ranges, the dose 
should be 0.15 mg/kg.46,47
Defecation can be expected within 4 hours after the first 
dose in about 50% of patients.39
Pharmacokinetics of 
methylnaltrexone bromide
Methylnaltrexone bromide is absorbed rapidly, with peak 
concentrations (Cmax) achieved at approximately 0.5 hours 
following subcutaneous administration. The Cmax and 
area under the plasma concentration-time curve (AUC) 
increase with dose increase from 0.15 mg/kg to 0.5 mg/kg 
in a dose-proportional manner. Absolute bioavailability 
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of a 0.30 mg/kg subcutaneous dose versus a 0.30 mg/kg 
intravenous dose is 82%.32,37
Methylnaltrexone undergoes moderate tissue distribution. 
The steady-state volume of distribution is approximately 
1.1 L/kg. Methylnaltrexone is minimally bound to human 
plasma proteins (11.0% to 15.3%) as determined by equi-
librium dialysis.32,37,48
Methylnaltrexone is metabolized to a modest extent in 
humans based on the amount of methylnaltrexone metabolites 
recovered from excreta. Conversion to methyl-6-naltrexol 
isomers and methylnaltrexone sulfate appears to be the pri-
mary pathway to metabolism. Each of the methyl-6-naltrexol 
isomers has somewhat less antagonist activity than the parent 
compound, and low exposure in plasma of approximately 
8% of the drug-related materials. Methylnaltrexone sulfate 
is an inactive metabolite and present in plasma at a level of 
approximately 25% of drug-related materials.
Methylnaltrexone is eliminated primarily as the unchanged 
active substance. Approximately half of the dose is excreted in 
the urine and somewhat less in feces. The terminal disposition 
half-life (t1/2) is approximately 8 hours.49
Adverse effects
The most common adverse effects are reported to be abdomi-
nal cramps and flatulence.32,40,44,45,49
In a phase III placebo-controlled trial in 133 patients with 
opioid-induced bowel dysfunction and advanced illness, 
abdominal pain was reported in 17% of patients (vs 13% pla-
cebo group), flatulence in 13% of patients (vs 7% of placebo 
group), and nausea in 11% (vs 7% of placebo group).39 Other, 
rare adverse side effects might be seen only with long-term 
use of methylnaltrexone and in larger populations than those 
previously studied. Further research is urgently needed to be 
able to develop guideline-supported therapeutic recommen-
dations for long-term use of methylnaltrexone for treatment 
of opioid-induced constipation in advanced illness.
Conclusion
Opioid-induced constipation is a frequent symptom in patients 
with advanced illness undergoing analgesic treatment with 
opioids and is mediated predominantly by opioid receptors 
in the gut. Opioid-induced constipation has to be treated 
rigorously or, as far possible, avoided altogether by means of 
prophylactic treatment. Although many treatment strategies 
are available, opioid-induced constipation still poses therapeu-
tic challenges, particularly in the treatment of patients with 
poor health status and advanced illness. Thorough knowledge 
of the pathophysiology of the symptoms of opioid-induced 
constipation is essential for targeted treatment. An alternative 
therapeutic strategy to conventional oral laxatives has evolved 
by selectively blocking peripheral opioid-receptors while 
maintaining desired action of opioids on central receptors 
that mediate analgesia. This concept has been validated by the 
clinical efficacy of methylnaltrexone. Methylnaltrexone may 
represent an important therapeutic option for patients with 
advanced illness who are suffering from opioid-induced con-
stipation and resistant to conventional oral laxative therapy.
Methylnaltrexone is better than placebo for reversal of 
opioid-mediated increase of gastrointestinal transit time 
and constipation. The advantage of methylnaltrexone over 
other conventional oral laxatives is that it can be given via 
different routes, which might be beneficial for terminally ill 
patients. Methylnaltrexone is an effective and a less invasive 
measure compared with rectal intervention, the effects of 
which may reduce patient quality of life. However, despite 
its high effectiveness, the use of methylnaltrexone may be 
limited by expense.
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